QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC

Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial

(2014) D E Ediebah et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)

(2013) C. Obasaju et al.   ANNALS OF ONCOLOGY

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

(2013) G. Chen et al.   ANNALS OF ONCOLOGY

Association between changes in quality of life scores and survival in non-small cell lung cancer patients

(2012) D. GUPTA et al.   EUROPEAN JOURNAL OF CANCER CARE

Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer

(2012) Maurice Pérol et al.   JOURNAL OF CLINICAL ONCOLOGY

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

(2012) Ji-Youn Han et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

(2012) Li Zhang et al.   LANCET ONCOLOGY

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

(2012) Luis Paz-Ares et al.   LANCET ONCOLOGY

Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis

(2012) Madhusmita Behera et al.   LUNG CANCER

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

(2012) Christopher G. Azzoli et al.   Journal of Oncology Practice

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy

(2011) B. Coudert et al.   ANNALS OF ONCOLOGY

Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)

(2011) Sumitra Thongprasert et al.   Journal of Thoracic Oncology

Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy

(2010) Semiha Akin et al.   European Journal of Oncology Nursing

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Strategies for Prolonged Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Panos Fidias et al.   JOURNAL OF CLINICAL ONCOLOGY

Are the Most Distressing Concerns of Patients With Inoperable Lung Cancer Adequately Assessed? A Mixed-Methods Analysis

(2010) Carol Tishelman et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of Therapy

(2009) Thomas E. Stinchcombe et al.   Journal of Thoracic Oncology

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

(2009) Tudor Ciuleanu et al.   LANCET

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE